• <strong>Small</strong> Molecules</br>for <strong>Big</strong> Clinical Needs<sup>TM</sup>
    Small Molecules
    for Big Clinical NeedsTM
    Oral drugs with proven safety and efficacy
  • <strong>Small</strong> Molecules</br>for <strong>Big</strong> Clinical Needs<sup>TM</sup>
    Small Molecules
    for Big Clinical NeedsTM
    Oral drugs with proven safety and efficacy
  • <strong>Small</strong> Molecules</br>for <strong>Big</strong> Clinical Needs<sup>TM</sup>
    Small Molecules
    for Big Clinical NeedsTM
    Oral drugs with proven safety and efficacy

ABOUT US

Can·Fite BioPharma

is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities.

The Company has an advanced pipeline of proprietary drug candidates in Phase II and Phase III clinical development which address inflammatory, liver and metabolic diseases.

Can-Fite's platform technology utilizes the Gi protein associated A3 adenosine receptor (A3AR) as a therapeutic target. A3AR is highly expressed in inflammatory, cancer and other pathological body cells whereas low expression is found in normal cells, suggesting that the receptor could be a unique target for pharmacological intervention.

The Company's compounds bind with nM affinity to the A3AR and initiate de-regulation of the NF-kB and the Wnt signal transduction pathways resulting in anti-inflammatory and anti-cancer effects.

CORPORATE PARTNERSHIPS

Piclidenoson for the treatment of psoriasis has been out-licensed to Cipher Pharmaceuticals in Canada, to Gebro Pharma GmbH in Spain, Switzerland & Austria, Kyongbo Pharm in Korea, to CMS  in China, Taiwan, Hong Kong and Macao.

Namodenoson for the treatment of Liver Cancer and NASH has been out-licensed  to Chong Kun Dang (CKD) Pharmaceutical in Korea and to CMS in China.